You are here

Preliminary Phase II Efficacy and Safety Results Presented for Macular Edema Treatment

SUNNYVALE, Calif., April 3 /PRNewswire/ -- Oculex Pharmaceuticals, Inc., a developer of innovative therapeutic products for the treatment of major, sight-threatening diseases of the eye, announced today that it will present preliminary results from its Phase 2 trial of Posurdex® at the 2003 meeting of the Association for Research in Vision and Ophthalmology (ARVO). The company will present three-month efficacy and safety data from its study of Posurdex as a treatment for persistent macular edema (PME). The ARVO meeting will be held May 4-9 in Fort Lauderdale, Florida. Oculex will present Posurdex results on Thursday, May 8th (Abstracts #4289, #4309 and #4311).

Posurdex, Oculex's lead product, is based on the company's proprietary biodegradable, sustained-release, intraocular drug delivery technology. This micro-sized product delivers dexamethasone, a corticosteroid known for its anti-inflammatory properties, directly to the targeted disease site. The Phase 2 trial is designed to evaluate potential improvements in visual acuity for PME patients treated with Posurdex. Enrollment of this randomized, multi-center study has been completed with more than 300 patients under evaluation, making it one of the largest Phase 2 ophthalmology trials conducted to date.

Macular edema is a sight-threatening condition that results from the swelling of the central retina or macula and is associated with diseases such as diabetic retinopathy, retinal vein occlusion and uveitis. Affecting more than 750,000 people in the U.S., macular edema is the leading cause of visual disabilities and blindness among individuals with diabetes. Persistent macular edema, or PME, is a chronic, unresolved form of macular edema that has failed to respond to laser therapy, the current standard of care.

About Oculex Pharmaceuticals

Oculex Pharmaceuticals, Inc. is a privately held company developing innovative therapeutic products for the treatment of major, sight-threatening diseases of the eye. The company has developed the first biodegradable, sustained-release implant system designed to deliver drugs directly into the eye. This novel and proprietary platform technology is intended to overcome the drug delivery challenges limiting the application of pharmaceuticals to the treatment of serious eye diseases. The company is using this unique technology platform to develop and commercialize its own proprietary brand name products that contain well-established generic compounds. In addition, Oculex is collaborating with strategic partners to develop and commercialize proprietary compounds for the treatment of diseases of the eye.

For further information, please visit Oculex's website at www.oculex.com.

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Acasti reports disappointing results for a second Omega-3-based drug
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks